Hau, P. and Koch, D. and Hundsberger, T. and Marg, E. and Bauer, B. and Rudolph, R. and Rauch, M. and Brenner, A. and Rieckmann, P. and Schuth, J. and Jauch, T. and Koch, H. and Bogdahn, U. (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. NEUROLOGY, 68 (9). pp. 688-690. ISSN 0028-3878,
Full text not available from this repository. (Request a copy)Abstract
We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | GLIOBLASTOMA-MULTIFORME; RECURRENT; RADIOTHERAPY; TRIALS; PLUS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Neurologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Dec 2020 09:23 |
| Last Modified: | 22 Dec 2020 09:23 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33170 |
Actions (login required)
 |
View Item |
